{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:21:50Z","timestamp":1759332110637,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11523-020-00778-y","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T10:05:46Z","timestamp":1607335546000},"page":"85-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA"],"prefix":"10.1007","volume":"16","author":[{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Raut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushal D.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean D.","family":"MacKnight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuvayu S.","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"issue":"5","key":"778_CR1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","volume":"93","author":"SM Ansell","year":"2018","unstructured":"Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704\u201315. https:\/\/doi.org\/10.1002\/ajh.25071.","journal-title":"Am J Hematol"},{"key":"778_CR2","unstructured":"National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Hodgkin Lymphoma. 2019. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html. Accessed 15 Oct 2019."},{"issue":"1","key":"778_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"778_CR4","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1097\/hs9.0000000000000149","volume":"2","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Andre M, Johnson P, Fossa A, Casasnovas O, Engert A. Controversies in the treatment of classical hodgkin lymphoma. HemaSphere. 2018;2(5):e149. https:\/\/doi.org\/10.1097\/hs9.0000000000000149.","journal-title":"HemaSphere."},{"key":"778_CR5","unstructured":"National Comprehensive Cancer Network\u00ae (NCCN\u00ae). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Hodgkin Lymphoma2019."},{"issue":"27","key":"778_CR6","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","volume":"30","author":"AA Moccia","year":"2012","unstructured":"Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era. J Clin Oncol. 2012;30(27):3383\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.41.0910.","journal-title":"J Clin Oncol"},{"issue":"3","key":"778_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1100340.","journal-title":"N Engl J Med"},{"issue":"2","key":"778_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116\u201332. https:\/\/doi.org\/10.3322\/caac.21438.","journal-title":"CA Cancer J Clin"},{"key":"778_CR9","unstructured":"Seattle Genetics, Inc. Highlights of Prescribing Information ADCETRIS (brentuximab vedotin). 2019. p. 1\u201312."},{"issue":"7","key":"778_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/annonc\/mdw169","volume":"27","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016;27(7):1317\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdw169.","journal-title":"Ann Oncol"},{"issue":"12","key":"778_CR11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562\u20136. https:\/\/doi.org\/10.1182\/blood-2016-02-699850.","journal-title":"Blood"},{"key":"778_CR12","unstructured":"Food and Drug Administration (FDA). Nivolumab (Opdivo) for Hodgkin Lymphoma. 2016. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/nivolumab-opdivo-hodgkin-lymphoma. Accessed 15 Oct 2019."},{"key":"778_CR13","unstructured":"Food and Drug Administration (FDA). Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma. 2017. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-classical-hodgkin-lymphoma. Accessed 15 Oct 2019."},{"issue":"14","key":"778_CR14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428\u201339. https:\/\/doi.org\/10.1200\/JCO.2017.76.0793.","journal-title":"J Clin Oncol"},{"issue":"9","key":"778_CR15","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(16)30167-X.","journal-title":"Lancet Oncol."},{"issue":"4","key":"778_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1411087.","journal-title":"N Engl J Med"},{"issue":"19","key":"778_CR17","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125\u201332. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316.","journal-title":"J Clin Oncol"},{"key":"778_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/CEOR.S178649","volume":"10","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Feliciano J, Cai Q, Noxon V, Princic N, Richhariya A, et al. Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. Clinicoecon Outcomes Res. 2018;10:629\u201341. https:\/\/doi.org\/10.2147\/CEOR.S178649.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"11","key":"778_CR19","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.3109\/10428194.2015.1030639","volume":"56","author":"CA Yasenchak","year":"2015","unstructured":"Yasenchak CA, Tseng WY, Yap M, Rembert D, Patt DA. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leuk Lymphoma. 2015;56(11):3143\u20139. https:\/\/doi.org\/10.3109\/10428194.2015.1030639.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"778_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res."},{"issue":"11","key":"778_CR21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"issue":"1","key":"778_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"key":"778_CR23","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2003","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2003.","edition":"5"},{"issue":"4","key":"778_CR24","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/bjc.2013.779","volume":"110","author":"LA Daniels","year":"2014","unstructured":"Daniels LA, Oerlemans S, Krol AD, Creutzberg CL, van de Poll-Franse LV. Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity. Br J Cancer. 2014;110(4):868\u201374. https:\/\/doi.org\/10.1038\/bjc.2013.779.","journal-title":"Br J Cancer"},{"issue":"4","key":"778_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11764-014-0367-1","volume":"8","author":"S Oerlemans","year":"2014","unstructured":"Oerlemans S, Mols F, Nijziel MR, Zijlstra WP, Coebergh JW, van de Poll-Franse LV. The course of anxiety and depression for patients with Hodgkin\u2019s lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry. J Cancer Surviv. 2014;8(4):555\u201364. https:\/\/doi.org\/10.1007\/s11764-014-0367-1.","journal-title":"J Cancer Surviv"},{"key":"778_CR26","unstructured":"Bristol-Myers Squibb Company. Highlights of Prescribing Information OPDIVO (nivolumab). 2019. p. 1\u201331."},{"key":"778_CR27","unstructured":"Merck & Co., Inc. Highlights of Prescribing Information KEYTRUDA\u00ae (pembrolizumab). 2019. p. 1\u201383."},{"issue":"7","key":"778_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","volume":"32","author":"T Kewalramani","year":"2003","unstructured":"Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin\u2019s disease or aggressive non-Hodgkin\u2019s lymphoma. Bone Marrow Transpl. 2003;32(7):673\u20139. https:\/\/doi.org\/10.1038\/sj.bmt.1704214.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"778_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/10428194.2018.1508665","volume":"60","author":"C Shao","year":"2019","unstructured":"Shao C, Liu J, Zhou W, Raut MK, Monberg M, Cao X, et al. Treatment patterns, health care resource utilization, and costs in patients with relapsed\/refractory Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2019;60(4):947\u201354. https:\/\/doi.org\/10.1080\/10428194.2018.1508665.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"778_CR30","doi-asserted-by":"publisher","first-page":"e0180261","DOI":"10.1371\/journal.pone.0180261","volume":"12","author":"SM Szabo","year":"2017","unstructured":"Szabo SM, Hirji I, Johnston KM, Juarez-Garcia A, Connors JM. Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: a retrospective cohort study. PLoS One. 2017;12(10):e0180261. https:\/\/doi.org\/10.1371\/journal.pone.0180261.","journal-title":"PLoS One"},{"issue":"6","key":"778_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/17474086.2018.1475226","volume":"11","author":"S Keeping","year":"2018","unstructured":"Keeping S, Wu E, Chan K, Mojebi A, Ferrante SA, Balakumaran A. Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin\u2019s lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. Expert Rev Hematol. 2018;11(6):503\u201311. https:\/\/doi.org\/10.1080\/17474086.2018.1475226.","journal-title":"Expert Rev Hematol."},{"issue":"7","key":"778_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","volume":"24","author":"SM Bair","year":"2019","unstructured":"Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, et al. Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in hodgkin lymphoma patients in the United States: a real-world. Multicenter retrospective analysis. Oncologist. 2019;24(7):955\u201362. https:\/\/doi.org\/10.1634\/theoncologist.2018-0538.","journal-title":"Oncologist."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-020-00778-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T20:15:58Z","timestamp":1610741758000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-020-00778-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00778-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2020,12,7]]},"assertion":[{"value":"7 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. MR, XY, AN, SSS, and KDD are employees of Merck & Co., Inc. FL, GG, and SDM are employees of Groupe d\u2019analyse, Lt\u00e9e, a consulting company that has received research funds from Merck & Co., Inc., to conduct this study. MSD is an employee of Analysis Group, Inc., a consulting company that has received research funds from Merck & Co., Inc., to conduct this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"The data for study participants were de-identified and complied with the Health Insurance Portability and Accountability Act (HIPAA); therefore, no reviews by an institutional review board were required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The present investigation was based on administrative claims data and does not contain any procedures with human participants performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors and persons named in the <i>Acknowledgements<\/i> section have given permission to be named in the article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Claims data used in the present study are accessible through the Symphony Health\u2019s IDV\u00ae (Integrated Dataverse) (from July 2014 to June 2018).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"All analyses were conducted using SAS Enterprise Guide Version 7.1 (SAS Institute, Cary, NC, USA).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"All authors were responsible for the study design and the interpretation of the study results. Fran\u00e7ois Lalibert\u00e9, Guillaume Germain, and Sean D. MacKnight were responsible for the data analysis. All authors reviewed the manuscript for intellectual content and approved the final draft. Medical writing assistance was provided by Christine Tam, an employee of Groupe d\u2019analyse, Lt\u00e9e, which received research funds from Merck & Co., Inc., to conduct this study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}